170 related articles for article (PubMed ID: 15972861)
1. Torcetrapib and atorvastatin--should marketing drive the research agenda?
Avorn J
N Engl J Med; 2005 Jun; 352(25):2573-6. PubMed ID: 15972861
[No Abstract] [Full Text] [Related]
2. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
[TBL] [Abstract][Full Text] [Related]
3. Torcetrapib and atorvastatin.
Shear CL
N Engl J Med; 2005 Oct; 353(14):1527-9; author reply 1527-9. PubMed ID: 16207861
[No Abstract] [Full Text] [Related]
4. Increasing HDL Cholesterol Levels.
Brewer HB
N Engl J Med; 2004 Apr; 350(15):1491-4. PubMed ID: 15071124
[No Abstract] [Full Text] [Related]
5. CETP inhibitors to increase HDL cholesterol levels.
Tall AR
N Engl J Med; 2007 Mar; 356(13):1364-6. PubMed ID: 17387130
[No Abstract] [Full Text] [Related]
6. Torcetrapib/atorvastatin combination therapy.
Bays H; McKenney J; Davidson M
Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):789-820. PubMed ID: 16181026
[TBL] [Abstract][Full Text] [Related]
7. Effect of torcetrapib on the progression of coronary atherosclerosis.
Nissen SE; Tardif JC; Nicholls SJ; Revkin JH; Shear CL; Duggan WT; Ruzyllo W; Bachinsky WB; Lasala GP; Tuzcu EM;
N Engl J Med; 2007 Mar; 356(13):1304-16. PubMed ID: 17387129
[TBL] [Abstract][Full Text] [Related]
8. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
Weizel A; Sawicki PT
MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
[No Abstract] [Full Text] [Related]
9. Atorvastatin: a new agent for hyperlipidemia.
Kupecz D
Nurse Pract; 1997 Nov; 22(11):87-8, 90, 93. PubMed ID: 9403876
[No Abstract] [Full Text] [Related]
10. [Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
März W
MMW Fortschr Med; 2004 Jul; 146(27-28):53. PubMed ID: 15526673
[No Abstract] [Full Text] [Related]
11. The failure of torcetrapib: was it the molecule or the mechanism?
Tall AR; Yvan-Charvet L; Wang N
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):257-60. PubMed ID: 17229967
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
McKenney JM; Davidson MH; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
[TBL] [Abstract][Full Text] [Related]
13. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
14. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway.
Catalano G; Julia Z; Frisdal E; Vedie B; Fournier N; Le Goff W; Chapman MJ; Guerin M
Arterioscler Thromb Vasc Biol; 2009 Feb; 29(2):268-75. PubMed ID: 19038848
[TBL] [Abstract][Full Text] [Related]
15. [To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
MMW Fortschr Med; 2005 Aug; 147(33-34):51. PubMed ID: 16138641
[No Abstract] [Full Text] [Related]
16. [AVERT [The Atorvastatin versus Revascularization Treatment]].
Mokuno H
Nihon Rinsho; 2001 Mar; 59 Suppl 3():436-41. PubMed ID: 11347110
[No Abstract] [Full Text] [Related]
17. Effect of chitosan on lipid levels when administered concurrently with atorvastatin--a placebo controlled study.
Guha S; Pal SK; Chatterjee N; Sarkar G; Pal S; Guha S; Basu AK; Banerjee R
J Indian Med Assoc; 2005 Aug; 103(8):418, 420. PubMed ID: 16363196
[TBL] [Abstract][Full Text] [Related]
18. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
19. Torcetrapib and atorvastatin.
Green AM
N Engl J Med; 2005 Oct; 353(14):1527-9; author reply 1527-9. PubMed ID: 16211710
[No Abstract] [Full Text] [Related]
20. Updated guidelines support even lower cholesterol levels for at-risk patients.
Levenson D
Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
[No Abstract] [Full Text] [Related]
[Next] [New Search]
